All … Available for Android and iOS devices. Epub 2013 Jan 12.Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, Dietrich L, Biggs D, Lafky JM, Loprinzi CL.N Engl J Med. As for safety profile, the drug‐related adverse events indicated there were no significant differences among olanzapine‐based, NK‐1RAs‐based, and duplex control regimens. Jadad scale was used to assess the quality of all included studies Another two investigators (HS and MY) assessed the risk of bias of the studies by using the risk of bias tool following the Cochrane Collaboration guidelines (Flow diagram of the study selection for the comparison of olanzapine‐based triple regimens and neurokinin‐1 receptor antagonists‐based regimens in patients with HEC.Abbreviations: AUC, area under the curve; CINV, chemotherapy‐induced nausea and vomiting; HEC, highly emetogenic chemotherapy; MEC, moderately emetogenic chemotherapy.First, we performed pair‐wise meta‐analyses with a random‐effect model to synthesize studies comparing olanzapine‐based triple regimens and NK‐1RAs‐based triple regimens. 2016 Jun;10(2):180-8. doi: 10.1097/SPC.0000000000000206.Chow R, Chiu L, Navari R, Passik S, Chiu N, Popovic M, Lam H, Pasetka M, Chow E, DeAngelis C.Support Care Cancer. All patients received standard premedication. For cancer patients with HEC, especially those suffering from delayed‐phase nausea, olanzapine‐based triple regimens should be an optional antiemetic choice.根据本研究的结果, 在接受高致吐性化疗 (HEC) 的患者中, 含奥氮平的三联止吐方案在全程和延迟期恶心控制方面的表现优于多种含神经激肽‐1 受体拮抗剂的三联方案。在控制恶心和药物价格方面, 含奥氮平的三联方案表现突出。对于接受 HEC 的癌症患者（特别是出现延迟期恶心的患者）, 含奥氮平的三联方案应成为一项止吐选择。Chemotherapy‐induced nausea and vomiting (CINV) are very common side effects that often discourage patients’ compliance with anticancer treatment and lead to a significant deterioration in quality of life Olanzapine is an atypical antipsychotic, approved by the U.S. Food and Drug Administration for the treatment of schizophrenia, mania, and bipolar disorder since 1996 [10, 11]. All authors saw and approved the final version of the manuscript. Analytical, Diagnostic and Therapeutic Techniques and Equipment 32 Our findings confirmed that olanzapine‐based triple regimens possessed a superior control of nausea, especially in the overall and delayed phases, in patients with HEC. (b) The participants were malignant tumor patients using HEC instead of moderately emetogenic chemotherapy (MEC; the emetogenic potential of chemotherapy was defined according to National Comprehensive Cancer Network [NCCN] Antiemesis Guideline Version 2, 2017) The proportion of patients in overall (0–120 hours), acute (0–24 hours after chemotherapy) and delayed (>24–120 hours after chemotherapy) phases (OP, AP, and DP, respectively), complete responses (CRs), and no nausea were the antiemetic efficacy outcomes in this study.